Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2016

22.07.2016 | Breast Oncology

Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer

verfasst von: Laura E. G. Warren, MD, EdM, Jennifer A. Ligibel, MD, Yu-Hui Chen, MPH, MS, Linh Truong, BSc, Paul J. Catalano, ScD, Jennifer R. Bellon, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Higher body mass index (BMI) has been associated with increased distant recurrence and decreased survival for women with breast cancer. However, the relationship between BMI and locoregional recurrence (LRR) has been less well studied and was therefore the subject of this investigation.

Methods

The study identified 878 women with early-stage invasive breast cancer who underwent breast-conservation therapy (BCT) between June 1997 and October 2007. Time from diagnosis to LRR was calculated using a competing risk analysis with contralateral breast cancer (CBC), distant metastases (DM), and death as the competing risks. Gray’s competing risks analysis, which included an interaction term between menopausal status and BMI, was used to identify significant risk factors for the development of LRR.

Results

After a median follow-up period of 10.8 years, LRR was diagnosed as a first event for 45 women. In a multivariable analysis, BMI was positively associated with LRR but only in premenopausal women. Specifically, when these women were compared with normal- and underweight women, both the overweight women (hazard ratio (HR), 2.97; 95 % confidence interval (CI) 1.04–8.46; p = 0.04) and the obese women (HR, 3.36; 95 % CI 1.07–10.63; p = 0.04) showed a higher risk of LRR. A similar association between BMI and disease-free survival was noted for premenopausal but not postmenopausal women.

Conclusion

For premenopausal women with invasive breast cancer who undergo BCT, BMI is an independent prognostic factor for LRR. If confirmed, these findings suggest that more aggressive treatment strategies may be warranted for these women.
Literatur
8.
Zurück zum Zitat Berclaz G, Li S, Price KN, Coates AS. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875–84. doi:10.1093/annonc/mdh222.CrossRefPubMed Berclaz G, Li S, Price KN, Coates AS. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875–84. doi:10.​1093/​annonc/​mdh222.CrossRefPubMed
9.
Zurück zum Zitat Bergom C, Kelly T, Bedi M, et al. Does size matter: examining the association of BMI with breast cancer recurrence and survival in an early-stage breast cancer cohort with a high median BMI. Int J Radiat Oncol. 2014;90:S47–S48. doi:10.1016/j.ijrobp.2014.05.176.CrossRef Bergom C, Kelly T, Bedi M, et al. Does size matter: examining the association of BMI with breast cancer recurrence and survival in an early-stage breast cancer cohort with a high median BMI. Int J Radiat Oncol. 2014;90:S47–S48. doi:10.​1016/​j.​ijrobp.​2014.​05.​176.CrossRef
11.
Zurück zum Zitat Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128–43.CrossRefPubMed Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128–43.CrossRefPubMed
12.
Zurück zum Zitat Tretli S, Haldorsen T, Ottestad L. The effect of premorbid height and weight on the survival of breast cancer patients. Br J Cancer. 1990;62:299–303.CrossRefPubMedPubMedCentral Tretli S, Haldorsen T, Ottestad L. The effect of premorbid height and weight on the survival of breast cancer patients. Br J Cancer. 1990;62:299–303.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Maehle BO, Tretli S. Premorbid body mass index in breast cancer: reversed effect on survival in hormone receptor-negative patients. Breast Cancer Res Treat. 1996;41:123–30.CrossRefPubMed Maehle BO, Tretli S. Premorbid body mass index in breast cancer: reversed effect on survival in hormone receptor-negative patients. Breast Cancer Res Treat. 1996;41:123–30.CrossRefPubMed
15.
Zurück zum Zitat Marret H, Perrotin F, Bougnoux P, et al. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat. 2001;66:17–23.CrossRefPubMed Marret H, Perrotin F, Bougnoux P, et al. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat. 2001;66:17–23.CrossRefPubMed
16.
Zurück zum Zitat Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73. doi:10.1200/JCO.2008.19.8424.CrossRefPubMedPubMedCentral Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73. doi:10.​1200/​JCO.​2008.​19.​8424.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
20.
Zurück zum Zitat Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRef Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRef
21.
Zurück zum Zitat Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;34:187–220. Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;34:187–220.
23.
Zurück zum Zitat Pike MC, Spicer D V, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–35.PubMed Pike MC, Spicer D V, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–35.PubMed
24.
Zurück zum Zitat Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A. Estrogen and progesterone receptors in breast cancer patients: epidemiologic characteristics and survival differences. Cancer. 1989;64:196–202.CrossRefPubMed Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A. Estrogen and progesterone receptors in breast cancer patients: epidemiologic characteristics and survival differences. Cancer. 1989;64:196–202.CrossRefPubMed
26.
Zurück zum Zitat Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720–9.CrossRefPubMed Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720–9.CrossRefPubMed
30.
33.
Zurück zum Zitat Pfeiler G, Königsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–9. doi:10.1200/JCO.2010.33.2585.CrossRefPubMed Pfeiler G, Königsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–9. doi:10.​1200/​JCO.​2010.​33.​2585.CrossRefPubMed
39.
Zurück zum Zitat Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327–34.PubMed Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327–34.PubMed
41.
Zurück zum Zitat Goodwin PJ, Segal RJ, Vallis M, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 2014;32:2231–9. doi:10.1200/JCO.2013.53.1517.CrossRefPubMed Goodwin PJ, Segal RJ, Vallis M, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 2014;32:2231–9. doi:10.​1200/​JCO.​2013.​53.​1517.CrossRefPubMed
42.
Zurück zum Zitat Thomson CA, Stopeck AT, Bea JW, et al. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs reduced-carbohydrate diets. Nutr Cancer. 2010;62:1142–52. doi:10.1080/01635581.2010.513803.CrossRefPubMed Thomson CA, Stopeck AT, Bea JW, et al. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs reduced-carbohydrate diets. Nutr Cancer. 2010;62:1142–52. doi:10.​1080/​01635581.​2010.​513803.CrossRefPubMed
Metadaten
Titel
Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer
verfasst von
Laura E. G. Warren, MD, EdM
Jennifer A. Ligibel, MD
Yu-Hui Chen, MPH, MS
Linh Truong, BSc
Paul J. Catalano, ScD
Jennifer R. Bellon, MD
Publikationsdatum
22.07.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5437-3

Weitere Artikel der Ausgabe 12/2016

Annals of Surgical Oncology 12/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.